Skip to main content
. 2003 Nov;9(11):1415–1422. doi: 10.3201/eid0911.030284

Table 3. Results of univariate analysis for MSSA casesa.

Risk factor MSSA cases (n = 163)
Demographic
No.
%
OR (95% CI)
p value
Male
91
55.8
1.89 (1.29 to 2.77)
0.001
Age
Mean = 63.3 y.



<50
42
25.8


51–75
68
41.7
1.50 (0.95 to 2.37)
0.08
>75
53
32.5
2.10 (1.27 to 3.45)
0.004
Coexisting condition




Cardiovascular disease
117
71.8
2.08 (1.39 to 3.13)
<0.001
Lung disease
61
37.4
2.95 (1.92 to 4.54)
<0.001
Renal disease
28
17.2
2.06 (1.17 to 3.62)
0.01
Hepatic disease
24
14.7
3.16 (1.64 to 6.10)
<0.001
Organ transplant
2
1.2
1.00 (0.18 to 5.60)
0.99
AIDS
1
0.6
0.39 (0.00 to 3.42)
0.40
Malignancy
30
18.4
1.21 (0.74 to 1.98)
0.46
Diabetes mellitus
38
23.3
1.25 (0.80 to 1.98)
0.33
Hospital factors




Transfer
29
17.8
2.11 (1.22 to 3.64)
0.01
Surgical procedure
62
38.0
0.78 (0.52 to 1.15)
0.20
ICU stay
89
54.6
6.38 (4.14 to 9.83)
<0.001
Intravenous line
50
30.7
1.99 (1.28 to 3.09)
0.002
Emergent admission
97
59.5
1.90 (1.30 to 2.79)
<0.001
Admission service




Medical
85
52.1


Obstetrical
3
1.8
0.10 (0.03 to 0.34)
<0.001
Surgical
75
46.0
1.49 (1.00 to 2.21)
0.05
Antimicrobial drugs




Any fluoroquinolone
37
22.7
0.96 (0.60 to 1.53)
0.86
Levofloxacin
24
14.7
1.09 (0.62 to 1.90)
0.77
Ciprofloxacin
14
8.6
0.74 (0.38 to 1.44)
0.37
Vancomycin
31
19.0
1.78 (1.04 to 3.05)
0.36
Penicillin
33
20.2
2.17 (1.28 to 3.66)
0.004
β-lactam and inhibitor
6
3.7
2.37 (0.70 to 8.06)
0.17
First-generation cephalosporin
27
16.6
0.65 (0.40 to 1.07)
0.09
Third-generation cephalosporin
18
11.0
1.21 (0.64 to 2.30)
0.56
Carbapenem
2
1.2
1.05 (0.17 to 6.48)
0.96
Clindamycin
6
3.7
1.35 (0.47 to 3.91)
0.58
Metronidazole 34 20.9 1.70 (1.02 to 2.83) 0.04

a MsSA, methicillin-susceptible Staphylococcus aureus; OR, odds ration; CI, confidence interval.